F1 Pharma have successfully completed the procedure leading to the reception of an authorisation for the manufacturing of medicinal products.
Following a positive result of the inspection carried out at our premises in terms of conformity with the Good Manufacturing Practice (GMP), the Main Pharmaceutical Inspectorate (GIF) granted F1 Pharma manufacturing authorization No. 077/0478/15.
The decision of GIF entitles F1 Pharma to perform activities related to the manufacturing of medical products, physicochemical research and batch certification.
Thus we are now in a position to widen our offer for the pharmaceutical industry with services quality control testing and release of commercial batches of medicinal products for market sale.
As a result of the transformation of F1 Pharma into a joint stock company, we submitted a request to the Chief Pharmaceutical Inspectorate for the amendment of our Manufacturing Authorisation. The Chief Pharmaceutical Inspectorate accepted the requested amendment and on 30 October 2019 issued a decision granting new authorisation for F1 Pharma S.A.
The extent of our authorization remains unchanged.
